Navigation Links
Pharmasset to Present at Canaccord Adams Conference
Date:8/5/2009

tment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates: RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys(R) plus Copegus(R) and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial.

Pegasys((R)) and Copegus((R) )are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche w
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
4. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
5. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
8. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
9. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
10. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
11. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Boulder, CO / Rootstown, OH (PRWEB) January 22, 2015 ... sensitive detection platform, announced today that it has received AOAC-PTM ... O26, O45, O1O3, O111, O121, and O145; collectively referred to ... (E. coli) O157, at 1 colony forming unit (cfu) per ...
(Date:1/22/2015)... 22, 2015 Dr. Greg Leyer of UAS ... Scripps Natural Supplements Pre-Conference seminar on probiotics in San Diego, ... annual continuing education conference for health care professionals. This year’s ... topic of probiotics in health. Dr. Leyer spoke about the ...
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... Novavax, Inc. (Nasdaq: NVAX ) today announced that ... press release to be issued after 8:00 a.m. Eastern Time on ... call to discuss its financial results at 10:00 a.m. Eastern Time ... Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other ...
... July 31 Insmed Inc. (Nasdaq: INSM ), ... conference call on Thursday, August 13(th), at 8:30 AM ET, ... Insmed intends to issue its quarterly financial results press ... , To participate in the live conference call, ...
... LA JOLLA, Calif., July 30 TorreyPines ... has cancelled its Special Meeting of Stockholders, scheduled for today at ... stockholder to vote upon a proposal to approve the liquidation and ... and Plan of Merger by and between TPTX and Raptor Pharmaceuticals ...
Cached Biology Technology:Insmed to Host Second Quarter 2009 Conference Call 2TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 2TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 3TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 4
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
(Date:1/22/2015)... 22, 2015   EyeLock, Inc. , a market leader of ... Steve Gerber to the new role of Senior Vice ... leading development of mobile platforms and wearable solutions for EyeLock,s ... innovation in the semiconductor industry to his role at EyeLock, ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... frequently causes gastric ulcers and is also one of the ... infection is also associated with another gastric cancer risk factor, ... Clinical Investigation , researchers led by Richard Peek at Vanderbilt ... -induced gastric cancer. Peek and colleagues found that low iron ...
... in German . The climate after ... was cool, later very warm and then cool again. Thanks ... as paleontologists from the University of Zurich have reconstructed. The ... atmosphere, initially gave rise to new, short-lived species. In the ...
... This press release is available in German . ... produce energy from waste in biogas plants. Researchers from Bielefeld ... to find out which microbes do the best job. They ... in selected biogas plants up and down Germany. From the ...
Cached Biology News:Ironing out the link between H. pylori infection and gastric cancer 2Ups and downs of biodiversity after mass extinction 2A giant puzzle with billions of pieces 2A giant puzzle with billions of pieces 3
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... staining is a technique used to reveal ... PicTure™-Double Staining Kit is a Zymed polymer ... antigens simultaneously in the same human cell ... antigens can be identified using two different ...
... The FLUOstar OPTIMA is a ... built for life science labs in ... four different measurement principles: Fluorescence ... applications Time-Resolved Fluorescence including ...
... Digital Clamp One can operate as a Voltage ... Conductance (Dynamic) Clamp in electrophysiology research applications. Performance ... conventional analog equipment. • ... recent advances in the capabilities of Digital Signal ...
Biology Products: